Patents Assigned to The United States of America as represented by the Department of Health and Human Services
  • Patent number: 10017494
    Abstract: The present invention relates to a process for preparing compound 1 that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compound 1 and substituted derivatives thereof.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: July 10, 2018
    Assignees: Mycovia Pharmaceuticals, Inc., The United States of America, as represented by the Department of Health and Human Services
    Inventors: William J. Hoekstra, Christopher M. Yates, Mark Behnke, Asaf Alimardanov, Scott A. David, Douglas Franklin Fry
  • Patent number: 9598703
    Abstract: An isolated linear nucleic acid molecule comprising in this order: a first adeno-associated virus (AAV) inverted terminal repeat (ITR), a nucleotide sequence of interest and a second AAV ITR, wherein said nucleic acid molecule is devoid of AAV capsid protein coding sequences. The said nucleic acid molecule can be applied to a host at repetition without eliciting an immune response. Methods for producing and purifying this nucleic acid molecule, and use of the same for therapeutic purposes are also provided.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: March 21, 2017
    Assignees: ASSOCIATION INSTITUT DE MYOLOGIE; UNIVERSITÉ PIERRE ET MARIE CURIE (PARIS 6); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; INSTITUT NATIONAL DE LA SANTÉ DE LAD RECHERCHE MÉDICALE, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH
    Inventors: Luis Garcia, Cyriaque Beley, Thomas Voit, Robert Michael Kotin, Lina Li
  • Patent number: 9526777
    Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebola virus (EBOV) or Marburg virus (MARV).
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: December 27, 2016
    Assignees: The United States of America as Represented by the Department of Health and Human Services, Glaxosmithkline Biologicals SA
    Inventors: Nancy J. Sullivan, Gary J. Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
  • Patent number: 9254319
    Abstract: We have developed DNA and viral vectors that can be used, alone or in combination, as a vaccine against one HIV clade, subtype, or recombinant form of HIV or against multiple HIV clades, subtypes, or recombinant forms. Moreover, the vectors can encode a variety of antigens, which may be obtained from one clade or from two or more different clades, and the antigens selected and/or the manner in which the vectors are formulated (e.g., mixed) can be manipulated to generate a protective immune response against a variety of clades (e.g., the clades to which a patient is most likely to be exposed; with the proportions of the components of the vaccine tailored to the extent of the patient's risk to a particular clade or clades).
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: February 9, 2016
    Assignees: Emory University, The United States of America as represented by The Department of Health and Human Services
    Inventors: Harriet Robinson, James Smith, Rama Amara, Bernard Moss, Salvatore T. Butera, Dennis Ellenberger
  • Publication number: 20150004132
    Abstract: We have developed DNA and viral vectors that can be used, alone or in combination, as a vaccine against one HIV clade, subtype, or recombinant form of HIV or against multiple HIV clades, subtypes, or recombinant forms. Moreover, the vectors can encode a variety of antigens, which may be obtained from one clade or from two or more different clades, and the antigens selected and/or the manner in which the vectors are formulated (e.g., mixed) can be manipulated to generate a protective immune response against a variety of clades (e.g., the clades to which a patient is most likely to be exposed; with the proportions of the components of the vaccine tailored to the extent of the patient's risk to a particular clade or clades).
    Type: Application
    Filed: December 20, 2013
    Publication date: January 1, 2015
    Applicants: EMORY UNIVERSITY, Centers for Disease Control and Prevention, The United States of America as Represented by the Department of Health and Human Services
    Inventors: Harriet Robinson, James Smith, Ram Amara, Bernard Moss, Salvatore T. Butera, Dennis Ellenberger
  • Patent number: 8916172
    Abstract: The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.
    Type: Grant
    Filed: January 10, 2011
    Date of Patent: December 23, 2014
    Assignees: Emory University, National Institute of Allergy and Infectious Diseases (NIAID), The United States of America, as represented by the Department of Health and Human Services
    Inventors: Bernard Moss, Linda Wyatt, Patricia Earl, Harriet L. Robinson
  • Patent number: 8829022
    Abstract: N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.
    Type: Grant
    Filed: October 11, 2011
    Date of Patent: September 9, 2014
    Assignees: Purdue Research Foundation, The United States of America as represented by the Department of Health and Human Services
    Inventors: Mark S. Cushman, Andrew E. Morrell, Muthukaman Nagarajan, Yves G. Pommier, Keli K. Agama, Smitha Antony
  • Patent number: 8628782
    Abstract: Disclosed herein are isolated immunogens including variant gp120 polypeptides. In an example, a variant gp120 polypeptide includes a deletion of at least 8 consecutive residues of the fourth conserved loop (C4) between residues 419 and 434 of gp120 according to HXB2 numbering. Also provided are isolated nucleic acid molecules encoding the disclosed isolated immunogens. In an example, an isolated nucleic acid molecule further includes a nucleic acid molecule encoding a hepatitis B surface antigen or a variant thereof. Compositions including the isolated immunogens including variant gp120 polypeptides are also disclosed. In some examples, a composition further includes a carrier protein, such as a hepatitis B surface antigen or a variant thereof (natural or recombinant). Viral-like particles are also provided including any of the disclosed isolated immunogens or compositions.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: January 14, 2014
    Assignee: The United States of America, as Represented by the Department of Health and Human Services
    Inventor: Ira Berkower
  • Patent number: 8615291
    Abstract: Method, system, and computer program method for detecting pathological fluctuations of physiological signals to diagnose human illness. The method comprises performing a sliding window analysis to find sequences in physiological signal data that match amplitude- and duration-adjusted versions of a template function to within a specified tolerance.
    Type: Grant
    Filed: March 15, 2010
    Date of Patent: December 24, 2013
    Assignees: National Institutes of Health (NIH), The United States of America as Represented by the Department of Health and Human Services
    Inventors: Randall Moorman, Douglas E. Lake, Abigail Flower, John B. Delos
  • Patent number: 8538507
    Abstract: Balloon probes, adapted for use in endoscopy and other medical procedures, are useful to obtain spectroscopic information reflected or emitted from a tissue of interest in the infrared spectral region. The information collected by the probe is useful in the diagnosis and treatment of disease. The invention also relates to methods utilizing these probes to analyze a surface of interest, in a minimally invasive manner, in connection with the diagnosis and treatment of disease.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: September 17, 2013
    Assignees: Hypermed Imaging, Inc., The United States of America as represented by the Department of Health and Human Services
    Inventors: Jenny E. Freeman, Charles R. Lambert, Michael J. Hopmeier, Edgar N. Lewis
  • Publication number: 20130073011
    Abstract: A method of treating spinal cord injury (SCI) includes transcutaneously irradiating at least a portion of a spinal environment of the patient with light having a power density of at least about 0.01 mW/cm2 at the portion of the spinal environment.
    Type: Application
    Filed: November 7, 2012
    Publication date: March 21, 2013
    Applicants: Henry M. Jackson Foundation for Advancement of Military Medicine, The United State of America as represented by the Department of Health and Human Services
    Inventors: The United State of America as represented by th, Henry M. Jackson Foundation for Advancement of
  • Publication number: 20130035363
    Abstract: Thalidomide analogs that modulate tumor necrosis factor alpha (TNF?) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.
    Type: Application
    Filed: October 10, 2012
    Publication date: February 7, 2013
    Applicants: The United States of America as represented by the Department of Health & Human Services, P2D INC.
    Inventors: Nigel H. Greig, Harold Holloway, Arnold Brossi, Xiaoxiang Zhu, Tony Giordano, Qian-sheng Yu, William D. Figg
  • Patent number: 8361710
    Abstract: The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of lung cancer. The invention also provides methods of identifying anti-lung cancer agents.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: January 29, 2013
    Assignees: The Ohio State University Research Foundation, The United States of America as represented by the Department of Health and Human Services
    Inventors: Carlo M. Croce, Nozomu Yanaihara, Curtis C. Harris
  • Patent number: 8338104
    Abstract: The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: December 25, 2012
    Assignees: The Ohio State University Research Foundation, The United States of America, as represented by the Department of Health and Human Services, National Institute of Health, Office of Technology Transfer
    Inventors: Carlo M. Croce, Curtis C. Harris, Aaron J. Schetter
  • Patent number: 8328857
    Abstract: A method of treating spinal cord injury (SCI) includes transcutaneously irradiating at least a portion of a spinal environment of the patient with light having a power density of at least about 0.01 mW/cm2 at the portion of the spinal environment.
    Type: Grant
    Filed: February 25, 2010
    Date of Patent: December 11, 2012
    Assignees: The United States of America as represented by the Department of Health and Human Services, Henry M. Jackson Foundation for the Advancement of Military Medicine
    Inventors: Juanita J. Anders, Ilko K. Ilev, Ronald W. Waynant, Kimberly R. Byrnes
  • Patent number: 8288530
    Abstract: Disclosed are methods of preparing a macromolecular conjugated ligand and a metal complex thereof. The metal complex is targeted for use as a contrast agent, for example, in MRI. The method of preparing a macromolecular conjugated ligand comprises: (a) providing a compound of formula (I) wherein R, A, and Pg are as defined herein, (b) reacting the compound of formula (I) with a macromolecular compound (e.g., dendrimer) in an organic solvent medium which is substantially free of water to obtain a macromolecular conjugated compound, and (c) removing the carboxyl-protecting groups to obtain a carboxyl-deprotected macromolecular conjugated compound. The metal complex can be prepared by reacting the carboxyl-deprotected macromolecular conjugated compound with an ion (e.g., Gd(III)). Also disclosed are two carboxyl-protected 1B4M-DTPA intermediate compounds.
    Type: Grant
    Filed: November 6, 2007
    Date of Patent: October 16, 2012
    Assignee: The United States of America, as represented by the Department of Health and Human Services
    Inventors: Martin W. Brechbiel, Heng Xu
  • Patent number: 8278458
    Abstract: Compounds represented by structural formulas described herein, such as Structural Formula (I): or a pharmaceutically acceptable salt thereof are useful in treating conditions such as metal overload, oxidative stress, and neoplastic and preneoplastic conditions.
    Type: Grant
    Filed: October 4, 2007
    Date of Patent: October 2, 2012
    Assignees: University of Florida Research Foundation, Inc., University of Florida, The United States of America as Represented by the National Institutes of Health (NIH), The United States of America as Represented by the Department of Health and Human Services
    Inventor: Raymond J. Bergeron, Jr.
  • Patent number: 8257925
    Abstract: A miniaturized assembly is provided whereby a fluid sample can be divided into a plurality of sample portions in retaining wells and the sample fluid can be displaced from open ends of the wells while simultaneously being sealed in the wells. A method of dividing a fluid sample using the assembly is also provided.
    Type: Grant
    Filed: May 16, 2011
    Date of Patent: September 4, 2012
    Assignees: Applied Biosystems, LLC, The United States of America, as represented Department of Health and Human Services
    Inventors: James F. Brown, Jonathan E. Silver
  • Patent number: 8258106
    Abstract: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.
    Type: Grant
    Filed: November 10, 2006
    Date of Patent: September 4, 2012
    Assignees: University of Iowa Research Foundation, Coley Pharmaceutical Group, Inc., The United States of America, as represented by the Department of Health and Human Services
    Inventors: Arthur M. Krieg, Joel N. Kline, Dennis Klinman, Alfred D. Steinberg
  • Patent number: 8217222
    Abstract: A method is described to identify secreted proteins identified with stages of malignancy of cancer. The proteins are initially identified by trapping them with a fluorescent protein containing vector that can insert in any gene. The secreted proteins are initially identified by their fluorescence. Secreted proteins identifying tumors with specific degrees of malignancy are isolated to determine if they can serve as markers of cancer progression.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: July 10, 2012
    Assignees: Anticancer, Inc., The United States of America as represented by the Department of Health and Human Services
    Inventors: Mingxu Xu, Yuying Tan, Levy Kopelovich